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Abstract
Background—Infection with hepatitis A and hepatitis B virus can increase the risk of morbidity 
and mortality in persons with chronic liver disease (CLD). The Advisory Committee on 
Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for 
persons with CLD.
Methods—Data from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally 
representative, in-person interview surveys of the non-institutionalized US civilian population, 
were used to assess self-reported HepA (≥1 and ≥2 doses) and HepB vaccination (≥1 and ≥3 
doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable 
logistic regression was used to identify factors independently associated with HepA and HepB 
vaccination among adults with CLD.
Results—Overall, 19.4% and 11.5% of adults aged ≥18 years with CLD reported receiving ≥1 
dose and ≥2 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults 
without CLD (p<0.05 comparing those with and without CLD, ≥1dose). Age, education, 
geographic region, and international travel were associated with receipt of ≥2 doses HepA vaccine 
among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving ≥1 
dose and ≥3 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults 
without CLD (p<0.05 comparing those with and without CLD, ≥1 dose). Age, education, and 
receipt of influenza vaccination in the past 12 months were associated with receipt of ≥3 doses 
HepB vaccine among adults with CLD. Among adults with CLD and ≥10 provider visits, only 
13.8% and 35.3% had received ≥2 doses HepA and ≥3 doses HepB vaccine, respectively.
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Conclusions—HepA and HepB vaccination among adults with CLD is suboptimal and missed 
opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate 
persons with CLD to increase vaccination among this population.
Keywords
Hepatitis A vaccination; Hepatitis B vaccination; chronic liver disease; National Health Interview 
Survey
Introduction
Chronic liver disease (CLD) is one of the leading causes of mortality in the United States, 
with an estimated 33,000 CLD-related deaths occurring in 2011 [1]. The prevalence of 
hepatitis A infection is higher in patients with chronic liver disease than in the general 
population [2]. Infection with hepatitis A virus (HAV) or hepatitis B virus (HBV) can result 
in severe complications and increase the morbidity and mortality in patients with chronic 
liver disease [3].
Both hepatitis A (HepA) and hepatitis B (HepB) vaccines are safe and effective in patients 
with mild to moderate CLD [4–6]. To reduce HAV and HBV super-infection in patients with 
chronic liver disease, the Advisory Committee on Immunization Practices (ACIP) 
recommends HepA and HepB vaccinations [7, 8]. A 2014 study showed that overall HepA 
vaccination coverage (≥2 doses) among adults aged ≥19 years with chronic liver conditions 
was 13.8%, and overall HepB vaccination coverage (≥ 3 doses) among adults aged ≥19 years 
with chronic liver conditions was 29.8% [9]. However, information on factors associated 
with HepA and HepB vaccination coverage among adults with CLD is limited. This study 
assessed HepA and HepB vaccination coverage and factors associated with vaccination 
among adults aged ≥18 years with chronic liver disease. This information can be utilized to 
develop strategies to increase HepA and HepB vaccination coverages among persons with 
CLD.
Methods
Study sample
Data were analyzed from respondents aged ≥18 years from the 2014 and 2015 National 
Health Interview Survey (NHIS), a probability-based annual household survey conducted by 
the National Center for Health Statistics of the Centers for Disease Control and Prevention 
[10, 11]. Four core modules were included in the surveys: the household composition 
section, family core, sample adult core, and sample child core. One adult per family in each 
sampled household of the sample adult core was randomly selected and asked to complete 
the sample adult questionnaire, including questions about receipt of vaccination. Survey 
methods were similar in both years and have been published previously [12]. All analyses 
are based on combined data from the 2014 and 2015 NHIS. The final response rates for the 
sample adult core were 58.9% and 55.2% for 2014 and 2015, respectively.
Respondents were asked “Have you ever received the hepatitis B vaccine?” and, if yes, “Did 
you receive at least 3 doses of the hepatitis B vaccine, or less than 3 doses?”; “Have you ever 
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received the hepatitis A vaccine?” and, if yes, “How many hepatitis A shots did you 
receive?”; and “Has a doctor or other health professional ever told you that you had any kind 
of chronic, or long-term liver condition?” For this study, persons self-reporting receipt of 2 
doses of HepA or 3 doses of HepB vaccine were considered to be fully vaccinated for HepA 
or HepB. Respondents with CLD were defined as those who answered “Yes” to the question 
“Has a doctor or other health professional ever told you that you had any kind of chronic, or 
long-term liver condition?”; otherwise they were considered to be without CLD. Additional 
NHIS questions were used to stratify vaccination coverage by age, sex, education, 
employment status, poverty status, health insurance coverage, race/ethnicity, region of 
residence, marital status, receipt of influenza vaccination in the past 12 months, whether or 
not respondent has a primary doctor, number of medical office visits in the past 12 months, 
having traveled to regions with intermediate or high prevalence of HAV or HBV infection 
(defined as travel outside of the USA since 1995 to location other than Europe, Japan, 
Australia, New Zealand, or Canada), and whether or not the respondent has diabetes.
Statistical analysis
All analyses were performed using SAS (version 9.3.2) callable SUDAAN (version 11.0.0). 
Point estimates for vaccination coverage and 95% confidence intervals were calculated. 
Estimates were weighted by age, sex and race/ethnicity to represent the U.S. non-
institutionalized civilian adult population. Survey procedures were used to account for the 
multi-staged, clustered and stratified sample design in NHIS. Bivariate analyses were 
conducted using Pearson chi-square tests to compare population distributions between those 
with and without CLD. T-tests were conducted to test differences in vaccination coverage 
between those with and without CLD status and differences within each demographic 
subgroup among those with and without CLD. Multivariable logistic regression models were 
used to assess factors independently associated with ≥2 dose HepA or ≥3 dose HepB 
vaccination coverage among adults with and without CLD. Adjusted prevalence differences 
and 95% confidence intervals for the associations between these factors and HepA or HepB 
vaccination coverage are presented.
Results
A total of 68,995 adults aged ≥ 18 years were included in the study, of which 927 (1.2% 
weighted) reported having CLD (Table 1). The majority of persons with CLD were aged ≥50 
years (69.6%), female (51.4%), not in the work force (57.2%), lived at or above poverty 
level (78.1%), had private or public insurance (48.3%, 42.9%, respectively), were non-
Hispanic white (67.7%), married (51.2%), received influenza vaccination within the past 12 
months (55.2%), had a primary doctor for health care (91.8%), and visited a doctor’s office 
at least once in the past 12 months (90.9%). Compared with those without CLD, persons 
with CLD were older, less educated, less likely to be employed and to ever have been 
married, and more likely to be below poverty level, have public health insurance, be 
divorced or separated, have received influenza vaccination in the past 12 months, have a 
primary doctor, have ≥10 medical office visits in the past 12 months, and have diabetes 
(Table 1).
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Overall, 19.4% of adults aged ≥18 years with CLD reported receiving at least 1 dose of 
HepA vaccine compared with 14.7% of those without CLD (p<0.05 comparing those with 
and without CLD for ≥1 dose, data not shown). Among adults aged ≥18 years with and 
without CLD, 11.5% and 9.1% reported receiving ≥2 doses of HepA vaccine, respectively 
(Table 2). Among adults with CLD, higher ≥2 dose HepA vaccination was associated with 
age 18–49 years, being a high school graduate, having a college education or higher, living 
in the West, and having traveled to regions with intermediate or high prevalence of HAV 
infection (Table 2). Among adults without CLD, higher ≥2 dose HepA vaccination was 
associated with age 18–49 years, having a high school education or higher, being employed, 
having private health insurance, being of non-Hispanic other race/ethnicity, living in regions 
other than the Northeast, never having been married, having received influenza vaccination 
in the past 12 months, having had at least one medical office visit in the past 12 months, and 
having traveled to regions with intermediate or high prevalence of HAV infection (Table 2).
In multivariable analysis, among adults with CLD, ≥2 dose HepA vaccination coverage was 
7.9 percentage points lower among those aged ≥65 years compared with those aged 18–49 
years. Coverage was 12.4 and 7.6 percentage points higher, respectively, among those with a 
high school education or a college degree or higher compared with those with less than a 
high school education, 12.1 percentage points higher among those from the western region 
compared with those from the Northeast, and 11.8 percentage points higher among those 
who had traveled to regions with intermediate or high prevalence of HAV infection 
compared with those who had not traveled to these regions, controlling for all other factors. 
Among adults without CLD, characteristics similar to those in persons with CLD that had 
differences in adjusted coverage compared with the respective reference groups included 
age, education, regions of residence and travel to regions with intermediate or high 
prevalence of HAV infection (Table 2).
Overall, 35.7% of adults with CLD reported receiving at least 1 dose of HepB vaccine 
compared with 30.2% of those without CLD (p<0.05 comparing those with and without 
CLD for ≥1 dose, data not shown). Among adults aged ≥18 years with and without CLD, 
29.1% and 24.7% reported receiving ≥3 doses of HepB vaccine, respectively (Table 3). 
Among adults with CLD, higher ≥3 dose HepB vaccination was associated with age 18–49 
years, having some college education or higher, living in the Midwest region, and being 
divorced or separated (Table 3). Among adults without CLD, higher ≥3 dose HepB 
vaccination was associated with age 18–49 years, being female, having a high school 
education or higher, being employed, living at or above the poverty level, having private 
health insurance, being of non-Hispanic other race/ethnicity, living in the Midwest or West 
regions, never having been married, having received influenza vaccination in the past 12 
months, having a primary doctor, having had at least one medical office visit in the past 12 
months, having traveled to regions with intermediate or high prevalence of HBV infection, 
and not having diabetes (Table 3).
In multivariable analysis, among adults with CLD, those aged ≥65 years had ≥3 dose HepB 
vaccination coverage 24.9 percentage points lower compared with those aged 18–49 years, 
those with some college or a college degree or higher had coverage 14.4 and 16.9 percentage 
points higher, respectively, compared with those with less than a high school education, and 
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those who received influenza vaccination within the past 12 months had coverage 8.0 
percentage points higher compared with those who had not received an influenza 
vaccination in the past 12 months, controlling for all other factors (Table 3). Among adults 
without CLD, characteristics similar to those in persons with CLD that had differences in 
adjusted coverage compared with the respective reference groups included age, education, 
and receipt of influenza vaccination in the past 12 months (Table 3). Having diabetes was 
not independently associated with HepB vaccination among persons with or without CLD.
Among adults with CLD and at least one or more visits with a provider during the previous 
12 months, 86.2% – 89.4% had not received HepA vaccine (Table 2); 64.7% – 74.0% had 
not received Hep B vaccine (Table 3). Among those with CLD and diabetes, 71.5% reported 
visits with a provider during the previous 12 months but were not vaccinated with HepB 
vaccine. Among adults with CLD with ≥10 office visits in the past 12 months, only 13.8% 
were fully vaccinated with HepA vaccine (Table 2) and only 35.3% were fully vaccinated 
with HepB vaccine (Table 3).
Discussion
A previous national survey reported that coverage with ≥1 dose HepA vaccine among adults 
with chronic liver disease increased from 13% in 1999 to 20% in 2008, and coverage with 
≥1 dose HepB vaccine among adults with chronic liver disease increased from 23% to 32% 
[13]. The findings in this report using combined data from 2014–2015 show coverage 
similar to that reported from 2008, with 19.4% of adults with CLD reporting receipt of ≥1 
dose HepA vaccine and 35.7% reporting receipt of ≥1 dose HepB vaccine. Unlike the 
previous survey, which found no differences in ≥1 dose HepA or HepB vaccination coverage 
between persons with and without CLD, we found that adults with CLD had significantly 
higher coverage of ≥1 dose of both vaccines compared with adults without CLD. However, 
full coverage for both vaccines did not differ between those with and without CLD, and 
remains suboptimal, with only 11.5% and 29.1% of adults with CLD reporting completion 
of the 2-dose HepA and 3-dose HepB vaccine series, respectively.
Missed opportunities for vaccination of persons with CLD have been previously reported, 
with physicians infrequently adhering to hepatitis vaccination guidelines [14–16]. A 
previous survey found that hepatologists recommended HepA vaccine for 63% and HepB 
vaccine for 60% of eligible patients with chronic liver disease referred to a liver clinic [15]. 
Among primary care physicians, one survey found that 31% reported assessing adult 
patients for hepatitis B risk factors and vaccinating those identified as high risk [17]. 
Another survey found that 30–40% of primary care physicians reported routine assessment 
of HepA vaccination status for all adult patients and 40–60% reported routine assessment of 
HepB vaccination status [18]. The current study highlights numerous missed opportunities 
for HepA or HepB vaccination of persons with CLD, including missed opportunities for 
HepB vaccination of those with both CLD and diabetes. HepB vaccination is recommended 
for all adults aged 19–59 years with diabetes mellitus (type 1 and type 2) as soon as possible 
after receiving a diagnosis of diabetes; unvaccinated adults aged ≥60 years may be 
vaccinated at the discretion of the treating physician after assessing their risk and the 
likelihood of an adequate immune response to vaccination [19]. Although >90% of 
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respondents with CLD report having a primary doctor, only 13.8% and 35.3% of those who 
had 10 or more doctor visits in the past 12 months were fully vaccinated with HepA or 
HepB vaccines, respectively, and only 27.1% of those with both CLD and diabetes were 
fully vaccinated with HepB vaccine. The findings in this report underscore the need to 
improve awareness among providers of the recommendation for HepB vaccination among 
persons with diabetes and to increase HepB vaccination in this population, particularly those 
with CLD.
Time constraints, cost and lack of adequate reimbursement for vaccination services, varying 
recommendations by government and national organizations, patients not disclosing high-
risk behaviors, patient non-adherence to multiple office visits, and patient refusal are 
commonly reported by physicians as barriers to vaccinating adult patients with HepA and 
HepB vaccines [16–18, 20]. Lack of knowledge among physicians regarding indications for 
HepA and HepB vaccination has also been reported to be a barrier to vaccination [20]. 
Studies have shown that a provider recommendation and offer for vaccination is strongly 
associated with patient vaccination [21]. To increase opportunities for assessment and 
offering of HepA and HepB vaccines to patients with indications for vaccination, evidence-
based interventions aimed at providers, such as provider reminders and standing orders for 
vaccination are recommended [21, 22].
We found that age, education level, geographic region, and travel history were independently 
associated with HepA vaccination among persons with CLD. These factors were similar to 
those associated with HepA vaccination among persons without CLD, and most are related 
to other indications for vaccination. Higher coverage among younger adults compared with 
those aged ≥65 years might reflect the aging of cohorts who were recommended to be 
vaccinated as children [23, 24]. Similarly, differences in coverage by region are likely a 
result of earlier HepA vaccine recommendations that included routine vaccination of 
children living in states and communities with high rates of HAV infection, which were 
concentrated in the western United States [24]. Travelers to countries with high or 
intermediate endemicity of hepatitis A have been recommended to be vaccinated with HepA 
vaccine since 1996 [23]. The association between coverage and educational level might be 
indicative of increased information-seeking behavior and a better understanding of the need 
of vaccination among more educated persons [25].
Age, education, and receipt of influenza vaccination have previously been identified as 
factors associated with HepB vaccination among those with CLD [13] and other populations 
recommended for HepB vaccination [26, 27]. Similar to HepA vaccination, we also found 
significantly lower HepB vaccination coverage among adults with CLD aged ≥50 years 
compared with those aged 18–49 years, likely due to universal HepB vaccine 
recommendations for children and “catch-up” recommendations for adolescents introduced 
in 1995 and 1999 [28–30]. Adults with CLD who had some college or above education had 
significantly higher coverage compared with those who had less than a high school 
education. Higher vaccination coverage among adults with higher education levels might be 
associated with increasing numbers of colleges and universities that require HepB 
vaccination for college entrance, as well as a better understanding of the need of vaccination 
[25, 31]. Higher HepB vaccination coverage among those who had influenza vaccination in 
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past twelve months could reflect patients’ or providers’ awareness of the need for 
vaccinations in general [26, 32].
Despite the ACIP recommendation that persons with diabetes should be vaccinated with 
HepB vaccine [19], adults with CLD and comorbid diabetes did not have higher coverage 
compared with those with CLD but without diabetes. Among adults without CLD in our 
bivariate analysis, persons with diabetes had lower coverage compared with those who did 
not have diabetes. This finding is consistent with a previous study [33], and might be due to 
the diabetic population being older, and older age being associated with decreased coverage.
The findings in this study are subject to several limitations. First, all data were self-reported 
and not verified by medical records, therefore might be subject to recall bias. While self-
reported HepA and HepB vaccination status among adults has been shown to be moderately 
sensitive and specific [34], recall bias might differ between patients with and without CLD if 
patients with CLD are more frequently asked about vaccination by their medical providers 
and thus more likely to recall vaccination. Second, the NHIS does not identify all persons 
who might be at increased risk for HAV and HBV infection, so important confounding 
factors might have been excluded from the multivariable model. Third, the NHIS does not 
include institutionalized persons such as those in the military or who are incarcerated. 
Indications for HepA and HepB vaccination might be different among those persons. Fourth, 
we do not have information on the vaccine type received by respondents. Respondents were 
considered to be fully vaccinated for HepA if they reported receipt of ≥2 doses of HepA 
vaccine; however, if HepA vaccine was received as part of the combination HepA and HepB 
vaccine (Twinrix) [35], 3 doses would be needed for full coverage. Fifth, nonresponse bias 
might remain after weighting adjustments. Finally, we have no information about immunity 
to HAV or HBV. Antibody screening prior to immunization is recommended in some 
populations with CLD and vaccination is not indicated for those with evidence of prior 
immunity [36]. The vaccination coverage estimates reported here might be underestimates of 
the total proportion of persons with CLD with immunity to HAV and HBV.
Conclusions
HepA and HepB vaccination coverage among adults with CLD is low, despite this 
population having numerous encounters with health care providers. Providers should adhere 
to recommendations to vaccinate persons with CLD and to the National Vaccine Advisory 
Committee’s standards for adult immunization practices, which include assessing the 
vaccination status of patients at every visit, strongly recommending needed vaccines, and 
either administering vaccine or referring patient to providers who can immunize [37]. 
Employing evidence-based interventions such as standing orders and provider reminders 
could also increase opportunities to vaccinate this population [21].
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